A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. (15th January 2017)

• Record Type: Journal Article
• Authors: Meng, Yong; Liu, Xuelu; Liu, Juan; Cheng, Xianliang
• Is Part Of: International journal of cardiology. Volume 227(2017)
• Page Start: 267
• Page End: 271
• Publication Date: 2017-01-15
• Subjects: ACEIs Angiotensin Converting Enzyme Inhibitors -- ARBs Angiotensin Receptor Blockers -- CHF Chronic Heart Failure -- CI Cardiac Index -- CO Cardiac Output -- GFR Glomerular Filtration Rate -- HR Heart Rate -- LVEF Left Ventricular Ejection Fraction -- METs Metabolic Equivalents -- MLHFQ Minnesota Living With Heart Failure Questionnaire -- 6MWT 6-Minute Walk Test -- NYHA New York Heart Association -- QoL Quality of Life -- SBP Systolic Blood Pressure -- SF-8 Short Form-8 Questionnaire -- VSAQ Veterans Specific Activity Questionnaire; Metoprolol -- Heart rate -- Quality of life -- Motor function -- Cardiac performance -- Heart failure; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.11.115
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: To prospectively evaluate the impact of metoprolol achieved heart rate (HR) on cardiac-motor function and quality of life (QoL) in chronic heart failure (CHF) patients. Methods and results: Between February 2013 to April 2016, association of HR reduction with haemodynamic indices, motor function and QoL in CHF patients with HR > 80 bpm receiving metoprolol 23.75 mg or 47.5 mg q.d was studied. Overall, 154 patients (median age, 66.39 years; males, n = 101; females, n = 53) were enrolled, whose average resting HR decreased significantly from baseline value of 82.72 ± 6.73 to 69.38 ± 3.57, 67.72 ± 2.61, 66.50 ± 3.14 and 64.86 ± 3.21 bpm in the 1st, 3rd, 6th and 12th months post metoprolol intervention, respectively ( P < 0.0001). Similarly, the ejection fraction (r = − 0.6461, P < 0.0001), cardiac output (r = − 0.5238, P < 0.0001), cardiac index (r = − 0.5378, P < 0.0001) and veterans specific activity questionnaire scores ( r = − 0.4088, P < 0.0001) were significantly associated with the reduction in HR after 12 months. The improvement in 6-min walk test was independent of HR reduction ( P = 0.005). Similarly, QoL as measured by short form-8 questionnaire (SF-8) but not Minnesota Living with Heart Failure was significantly improved at the 12th–month. However, this was not associated with the reductions in HR. Conclusion: Metoprolol achieved HR control was associated with improvement in cardiac performance and motor function but not QoL in patients with CHF.